WP_Query Object
(
[query] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
)
[query_vars] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
[error] =>
[m] =>
[p] => 0
[post_parent] =>
[subpost] =>
[subpost_id] =>
[attachment] =>
[attachment_id] => 0
[name] =>
[pagename] =>
[page_id] => 0
[second] =>
[minute] =>
[hour] =>
[day] => 0
[monthnum] => 0
[year] => 0
[w] => 0
[category_name] =>
[tag] =>
[cat] =>
[tag_id] =>
[author] =>
[author_name] =>
[feed] =>
[tb] =>
[paged] => 0
[meta_key] =>
[meta_value] =>
[preview] =>
[s] =>
[sentence] =>
[title] =>
[fields] =>
[menu_order] =>
[embed] =>
[category__in] => Array
(
)
[category__not_in] => Array
(
)
[category__and] => Array
(
)
[post__in] => Array
(
)
[post__not_in] => Array
(
)
[post_name__in] => Array
(
)
[tag__in] => Array
(
)
[tag__not_in] => Array
(
)
[tag__and] => Array
(
)
[tag_slug__in] => Array
(
)
[tag_slug__and] => Array
(
)
[post_parent__in] => Array
(
)
[post_parent__not_in] => Array
(
)
[author__in] => Array
(
)
[author__not_in] => Array
(
)
[search_columns] => Array
(
)
[ignore_sticky_posts] =>
[suppress_filters] =>
[cache_results] => 1
[update_post_term_cache] => 1
[update_menu_item_cache] =>
[lazy_load_term_meta] => 1
[update_post_meta_cache] => 1
[nopaging] =>
[comments_per_page] => 50
[no_found_rows] =>
[order] =>
)
[tax_query] => WP_Tax_Query Object
(
[queries] => Array
(
)
[relation] => AND
[table_aliases:protected] => Array
(
)
[queried_terms] => Array
(
)
[primary_table] => wp_posts
[primary_id_column] => ID
)
[meta_query] => WP_Meta_Query Object
(
[queries] => Array
(
)
[relation] =>
[meta_table] =>
[meta_id_column] =>
[primary_table] =>
[primary_id_column] =>
[table_aliases:protected] => Array
(
)
[clauses:protected] => Array
(
)
[has_or_relation:protected] =>
)
[date_query] =>
[request] => SELECT SQL_CALC_FOUND_ROWS wp_posts.ID
FROM wp_posts
WHERE 1=1 AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
ORDER BY RAND()
LIMIT 0, 3
[posts] => Array
(
[0] => WP_Post Object
(
[ID] => 4488
[post_author] => 4
[post_date] => 2024-10-24 10:45:00
[post_date_gmt] => 2024-10-24 14:45:00
[post_content] =>
Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.
The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.
New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.
A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment would provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.
New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.
Read the press release of Governor Hochul's announcement here:
https://www.governor.ny.gov/news/governor-hochul-launches-next-phase-long-islands-nation-leading-cell-and-gene-therapy
[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park
[to_ping] =>
[pinged] =>
[post_modified] => 2024-12-05 11:35:07
[post_modified_gmt] => 2024-12-05 16:35:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4488
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 1246
[post_author] => 3
[post_date] => 2014-08-12 17:20:57
[post_date_gmt] => 2014-08-12 17:20:57
[post_content] => Proskauer recently released a comprehensive U.S. IPO Analysis. The study examines key factors and aspects of the U.S. IPO market and provides market participants with extensive data about deal structures and terms, SEC comments and timing, financial profiles and accounting disclosures, corporate governance, and expenses. It also includes separate industry sections on health care, TMT, consumer/retail, financial services and industrials. Read the full study here: http://www.proskauer.com/files/uploads/Documents/Proskauer-2014-IPO_Study.pdf
[post_title] => Proskauer Releases 2014 IPO Study
[post_excerpt] => Proskauer recently released a comprehensive U.S. IPO Analysis.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => proskauer-releases-2014-ipo-study
[to_ping] =>
[pinged] =>
[post_modified] => 2015-01-28 17:03:47
[post_modified_gmt] => 2015-01-28 17:03:47
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/new/?p=1246
[menu_order] => 223
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 3942
[post_author] => 4
[post_date] => 2022-10-24 15:40:45
[post_date_gmt] => 2022-10-24 15:40:45
[post_content] =>
The Long Island Network for Clinical and Translational Science (LINCATS) is awarding pilot funding of up to $25K per investigator with projects of novel approaches to translational science. This is open to faculty and postdoctoral fellows from the LINCATS network. Up to 8 awards will be granted per year – 4 of which will be provided to principal investigators from collaborating institutions, and 4 for SBU investigators.
Eligibility: All postdoctoral fellows and faculty affiliated with the LINCATS network (Brookhaven National Laboratory, Cold Spring Harbor, Northport VA Medical Center, Stony Brook University and all Stony Brook Medicine-affiliated healthcare locations) are eligible to apply. We will prioritize early career, under-represented groups, women, health disparities-focused clinical and translational science, and collaborative projects across institutions. Preference will be given to non-funded and new lines of research for the applying investigator.
Awardees will also benefit from research support from our Research Concierge, providing aid in:
Regulatory submission through approval
Data Capture and OnCore subject tracking
Pilot Tracking, to ensure the project meets specified milestones, including timely reporting
Resource Access to all LINCATS services
Monitoring and projecting study budgets
Learn more and click here to apply: https://www.stonybrookmedicine.edu/LINCATS/LINCATSPilots
[post_title] => Pilot Awards for Translational Science: LINCATS
[post_excerpt] => The Long Island Network for Clinical and Translational Science (LINCATS) is awarding pilot funding of up to $25K per investigator with projects of novel approaches to translational science.
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pilot-awards-for-translational-science-lincats
[to_ping] =>
[pinged] =>
[post_modified] => 2023-07-10 12:41:18
[post_modified_gmt] => 2023-07-10 16:41:18
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=3942
[menu_order] => 16
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 2878
[post_author] => 1
[post_date] => 2017-11-21 14:36:09
[post_date_gmt] => 2017-11-21 14:36:09
[post_content] => The proposal submission deadline for the SUNY Technology Accelerator Fund Class of 2018 is February 16, 2018.
Faculty, staff, and students from all disciplines and campuses are encouraged to submit proposals for the SUNY Technology Accelerator Fund Class of 2018 funding. The deadline for submitting proposals is February 16, 2018. See TAF Class of 2018 Application and Administrative Guidelines.
The SUNY Technology Accelerator Fund (“TAF”) provides funding to support the advancement of SUNY innovations from the lab to the marketplace. Since its launch in 2011, the TAF has successfully advanced the commercial readiness of a number of SUNY-developed innovations. In most cases, SUNY innovations developed through sponsored research lack critical proof-of-concept data that is needed to attract investment by potential licensees or investors. TAF support targets the critical milestones needed to demonstrate that an innovation is worthy of external investment. TAF’s strategic objective is to facilitate the commercialization of SUNY-developed innovations for the public benefit in an expeditious and effective manner. The aim is to identify opportunities where small investments will provide significant impacts on making SUNY innovations available to the public. Different from fundamental research, TAF investments support proof-of-concept and technology development projects to validate the commercial feasibility of SUNY technology. The goal is to facilitate the translation of SUNY technology into marketable products and/or services by enhancing strategic academic-industry partnerships and building new entrepreneurial
Please be advised that all proposals require the review and participation of your campus administration prior to submission. To be certain that you adhere to any local proposal submission deadlines, we urge you to immediately contact your technology transfer office and/or office of sponsored programs if you are interested in applying for TAF Class of 2018 funding.
Questions? Please send any questions to TAF@rfsuny.org. All questions and answers will be posted to www.rfsuny.org/taf.
[post_title] => Funding Opportunity: SUNY Technology Accelerator Fund Accepting Proposals
[post_excerpt] => Proposal Deadline for the SUNY Technology Accelerator Fund Class of 2018 is February 16, 2018! SUNY Technology Accelerator Fund (“TAF”) provides funding to support the advancement of SUNY innovations from the lab to the marketplace.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => funding-opportunity-suny-technology-accelerator-fund-accepting-proposals-2
[to_ping] =>
[pinged] =>
[post_modified] => 2018-01-23 14:38:56
[post_modified_gmt] => 2018-01-23 14:38:56
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/?p=2878
[menu_order] => 135
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 4
[current_post] => -1
[before_loop] => 1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 4488
[post_author] => 4
[post_date] => 2024-10-24 10:45:00
[post_date_gmt] => 2024-10-24 14:45:00
[post_content] =>
Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.
The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.
New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.
A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment would provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.
New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.
Read the press release of Governor Hochul's announcement here:
https://www.governor.ny.gov/news/governor-hochul-launches-next-phase-long-islands-nation-leading-cell-and-gene-therapy
[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park
[to_ping] =>
[pinged] =>
[post_modified] => 2024-12-05 11:35:07
[post_modified_gmt] => 2024-12-05 16:35:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4488
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[comment_count] => 0
[current_comment] => -1
[found_posts] => 259
[max_num_pages] => 87
[max_num_comment_pages] => 0
[is_single] =>
[is_preview] =>
[is_page] =>
[is_archive] =>
[is_date] =>
[is_year] =>
[is_month] =>
[is_day] =>
[is_time] =>
[is_author] =>
[is_category] =>
[is_tag] =>
[is_tax] =>
[is_search] =>
[is_feed] =>
[is_comment_feed] =>
[is_trackback] =>
[is_home] => 1
[is_privacy_policy] =>
[is_404] =>
[is_embed] =>
[is_paged] =>
[is_admin] =>
[is_attachment] =>
[is_singular] =>
[is_robots] =>
[is_favicon] =>
[is_posts_page] =>
[is_post_type_archive] =>
[query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0
[query_vars_changed:WP_Query:private] =>
[thumbnails_cached] =>
[allow_query_attachment_by_filename:protected] =>
[stopwords:WP_Query:private] =>
[compat_fields:WP_Query:private] => Array
(
[0] => query_vars_hash
[1] => query_vars_changed
)
[compat_methods:WP_Query:private] => Array
(
[0] => init_query_flags
[1] => parse_tax_query
)
)
